Reuters logo
BRIEF-Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation
July 17, 2017 / 11:26 AM / in 5 months

BRIEF-Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation

July 17 (Reuters) - Axsome Therapeutics Inc

* Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below